Dr. Zhukovsky has more than 25 years of professional experience in the field of biotherapeutics research and development. Prior to joining BIOMUNEX as Chief Scientific Officer in January 2015, Dr. Zhukovsky was Chief Scientific Officer of Affimed Therapeutics since 2011. Prior to that, he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim Pharmaceuticals, Inc. Prior to that, Dr. Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research efforts resulting in several therapeutic candidates targeting malignant and normal B cells.
Dr. Zhukovsky began his professional career employing phage display technology at Neurex Corporation (now Perrigo Company). Dr. Zhukovsky then moved to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies before returning to protein/antibody engineering and biotherapeutics development at Xencor, Inc.Dr. Zhukovsky received a Ph.D. in biochemistry from Brandeis University (Waltham, USA) and was a postdoctoral fellow at Genentech.